By Fineline Cube Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation reactivator, has received U.S. FDA Orphan Drug Designation (ODD) for the treatment of pancreatic cancer. The Class 1 innovative chemical drug in China, which restores normal conformation and transcriptional activity of the mutant TP53 protein, holds IND approvals from both FDA and NMPA for locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation, including pancreatic, ovarian, breast, and colorectal cancers.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Designation | Orphan Drug Designation (ODD) |
| Product | GenSci128 tablets |
| Drug Class | Selective small-molecule TP53 Y220C mutation reactivator – Class 1 innovative chemical drug (China) |
| Indication (ODD) | Pancreatic cancer |
| Broader Indications | TP53 Y220C-mutant locally advanced/metastatic solid tumors (pancreatic, ovarian, breast, colorectal) |
| Developer | Changchun GeneScience Pharmaceutical Inc. – independently developed |
| U.S. Regulatory Pathway | 505(b)(1) – new molecular entity |
| Prior Approvals | • FDA IND approved • NMPA China clinical trial approved |
| Designation Date | 11 Mar 2026 |
Drug Profile & Mechanism
| Attribute | GenSci128 Specification |
|---|---|
| Target | TP53 Y220C mutant protein (structural mutation in DNA-binding domain) |
| Mechanism | • Selective binding to Y220C mutant pocket • Restores normal protein conformation • Increases mutant protein stability • Reactivates transcriptional activity • Restores tumor-suppressive functions |
| Drug Class | Small-molecule mutant p53 reactivator (first-in-class potential) |
| Preclinical Profile | Favorable efficacy and safety demonstrated |
| Route | Oral tablets |
| Innovation Status | Class 1 innovative chemical drug (China); 505(b)(1) pathway (U.S.) |
Scientific Rationale:
- TP53 Y220C: Structural mutation creates druggable pocket; ~1% of all cancers; enriched in pancreatic (2-3%), ovarian, breast, colorectal
- Loss of Function: Mutant p53 loses tumor suppression; gain-of-function oncogenic properties
- Reactivation Strategy: Small molecule binding restores wild-type conformation → transcriptional activation of p53 target genes (p21, PUMA, Bax) → cell cycle arrest/apoptosis
Strategic Context & Market Opportunity
| Factor | Implication |
|---|---|
| Pancreatic Cancer Burden | 60,000+ U.S. cases annually; 5-year survival <10%; TP53 mutations in 50-75% (Y220C subset addressable) |
| TP53 Drugability | Historically “undruggable” target; GenSci128 first-in-class reactivation approach validates new paradigm |
| ODD Benefits | 7-year market exclusivity; tax credits; waived FDA fees; protocol assistance; priority review eligibility |
| China-U.S. Parallel | Dual IND approvals enable global development; China data supports U.S. registration |
| Biomarker Strategy | Companion diagnostic for TP53 Y220C mutation required; liquid biopsy potential for patient identification |
Competitive Landscape
| Approach | Product/Platform | Developer | Status | GenSci128 Differentiation |
|---|---|---|---|---|
| KRAS inhibitors | Sotorasib, adagrasib | Amgen, Mirati/BMS | Approved (G12C) | TP53 vs. KRAS target; different patient population |
| Immunotherapy | Pembrolizumab, nivolumab | Merck, BMS | Approved (MSI-H) | Direct tumor suppressor reactivation vs. immune modulation |
| Other p53 approaches | APR-246 (eprenetapopt), PC14586 | Aprea, p53-Therapeutics | Phase II/III | GenSci128 Y220C-specific vs. broad mutant p53; potentially better selectivity |
| Changchun GeneScience | GenSci128 | TP53 Y220C reactivator | Phase I-ready; ODD | First-in-class selective Y220C reactivator; oral convenience |
Development Outlook
| Phase | Timeline | Objectives |
|---|---|---|
| Phase I | 2025-2027 (ongoing/planned) | Safety, tolerability, MTD; pharmacokinetics; TP53 Y220C biomarker validation |
| Phase II | 2027-2029 | Efficacy signals in pancreatic, ovarian, breast, colorectal; expansion cohorts |
| Regulatory Strategy | 2029-2030 | Accelerated approval via ODD; Breakthrough Therapy designation pursuit; NDA/MAA filings |
| Companion Diagnostic | 2026-2028 | TP53 Y220C mutation detection assay development and validation |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, TP53 reactivation mechanism validation, and competitive positioning for GenSci128. Actual results may differ due to mutant p53 biology complexity, biomarker testing adoption, and competitive dynamics with other tumor suppressor-targeted therapies.-Fineline Info & Tech